[Dr.Vad]

Лечебный эффект феринджекта при лечении пациентов с фибромиалгией и дефицитом железа лишь незначительно превзошел плацебо-эффект:

The efficacy analysis group comprised 80 patients, and the safety analysis group comprised 81. More ferric carboxymaltose patients (77%) vs. placebo patients (67%) achieved the primary endpoint, but the difference was not significant. Greater improvements from baseline to day 42 were observed for ferric carboxymaltose vs. placebo in FIQR total score, BPI total score, Fatigue VNS score, and iron indices.

A Blinded, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Ferric Carboxymaltose in Iron-Deficient Patients with Fibromyalgia

[Ссылки доступны только зарегистрированным пользователям ]